Dalacin C 150/Sterile Solution Dosage/Direction for Use

Dosage in Adults: Clindamycin phosphate IM administration should be used undiluted.
Clindamycin phosphate IV administration should be diluted (see Special Precautions for Disposal and Other Handling under Cautions for Usage).
Clindamycin phosphate (IM or IV administration): The usual daily adult dosage of clindamycin phosphate for infections of the intra-abdominal area, female pelvis, and other complicated or serious infections is 2400-2700 mg given in 2, 3, or 4 equal doses. Less complicated infections due to more susceptible microorganisms may respond to lower doses such as 1200-1800 mg/day administered in 3 or 4 equal doses.
Doses of up to 4800 mg daily have been used successfully.
Single IM doses of greater than 600 mg are not recommended.
Clindamycin hydrochloride capsules (oral administration): 600-1800 mg/day divided in 2, 3 or 4 equal doses. To avoid the possibility of esophageal irritation, clindamycin HCl capsules should be taken with a full glass of water.
Dosage in Children (from 2 years of age): Clindamycin should be dosed based on total body weight regardless of obesity.
Clindamycin phosphate (IM or IV administration): 20-40 mg/kg/day in 3 or 4 equal doses.
Clindamycin hydrochloride capsules (oral administration) for children who are able to swallow capsules: To avoid the possibility of esophageal irritation, clindamycin HCl capsules should be taken with a full glass of water. Clindamycin capsules are not suitable for children who are unable to swallow them whole.
Doses of 8-25 mg/kg/day in 3 or 4 equal doses.
Dosage in Elderly: Pharmacokinetic studies with clindamycin have shown no clinically important differences between young and elderly subjects with normal hepatic function and normal (age-adjusted) renal function after oral or intravenous administration. Therefore, dosage adjustments are not necessary in the elderly with normal hepatic function and normal (age-adjusted) renal function (see Pharmacology: Pharmacokinetics under Actions).
Dosage in Renal Impairment: Clindamycin dosage modification is not necessary in patients with renal insufficiency.
Dosage in Hepatic Impairment: Clindamycin dosage modification is not necessary in patients with hepatic insufficiency.
Dosage in Specific Indications: (a) Treatment of Beta-Hemolytic Streptococcal Infections: Refer to the dosage recommendations previously mentioned. Treatment should be continued for at least 10 days.
(b) Inpatient Treatment of Pelvic Inflammatory Disease: Clindamycin phosphate 900 mg (IV) every 8 hours daily plus an antibiotic with an appropriate gram-negative aerobic spectrum administered IV, e.g., gentamicin 2.0 mg/kg followed by 1.5 mg/kg every 8 hours daily in patients with normal renal function. Continue (IV) drugs for at least 4 days and at least 48 hours after the patient improves. Then continue oral clindamycin hydrochloride 450-600 mg q6h daily to complete 10-14 days total therapy.
(c) Treatment of Chlamydia trachomatis Cervicitis: Clindamycin hydrochloride capsules orally 450 mg 4 times daily for 10-14 days.
(d) Treatment of Toxoplasmic Encephalitis in Patients with AIDS: Clindamycin phosphate IV or clindamycin hydrochloride orally 600-1200 mg every 6 hours for 2 weeks followed by 300-600 mg orally every 6 hours. The usual total duration of therapy is 8 to 10 weeks. The dose of pyrimethamine is 25 to 75 mg orally each day for 8 to 10 weeks. Folinic acid 10 to 20 mg/day should be given with higher doses of pyrimethamine.
(e) Treatment of Pneumocystis jiroveci (previously classified as Pneumocystis carinii) Pneumonia in Patients with AIDS: Clindamycin phosphate IV 600 to 900 mg every 6 hours or 900 mg IV every 8 hours or clindamycin hydrochloride 300 to 450 mg orally every 6 hours for 21 days; and Primaquine 15 to 30 mg dose orally once daily for 21 days.
(f) Treatment of Acute Streptococcal Tonsillitis/Pharyngitis: Clindamycin hydrochloride capsules 300 mg orally twice daily for 10 days.